Fluorescently detectable magnetic resonance imaging agents.
about
Core/shell quantum dots with high relaxivity and photoluminescence for multimodality imagingMultimodality and nanoparticles in medical imagingMolecular imaging agents: impact on diagnosis and therapeutics in oncologyExogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging.Labeling and Imaging of Stem Cells - Promises and ConcernsIn vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumorsMacromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential?A multimeric MR-optical contrast agent for multimodal imagingBioconjugation of luminescent silicon quantum dots to gadolinium ions for bioimaging applications.Use of a genetically engineered protein for the design of a multivalent MRI contrast agent.Toward preparation of antibody-based imaging probe libraries for dual-modality positron emission tomography and fluorescence imaging.Bioresponsive, cell-penetrating, and multimeric MR contrast agents.Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticlesLanthanide(III) complexes of rhodamine-DO3A conjugates as agents for dual-modal imagingFate maps old and new.Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.Multimodality imaging probes: design and challenges.Assessing gene expression in vivo: magnetic resonance imaging and spectroscopy.Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agentsProtein polymer MRI contrast agents: Longitudinal analysis of biomaterials in vivo.Labeling fibroblasts with biotin-BSA-GdDTPA-FAM for tracking of tumor-associated stroma by fluorescence and MR imagingCell-specific targeting of nanoparticles by multivalent attachment of small molecules.Synthesis and characterization of new porphyrazine-Gd(III) conjugates as multimodal MR contrast agentsIn vivo monitoring of cellular transplants by magnetic resonance imaging and positron emission tomography.Multimeric Near IR-MR Contrast Agent for Multimodal In Vivo Imaging.A Dendritic Supramolecular Complex as Uniform Hybrid Micelle with Dual Structure for Bimodal In Vivo Imaging.Fluorescent nanoparticle probes for cancer imaging.Analysis of Lanthanide Complex Dendrimer Conjugates for Bimodal NIR and MRI Imaging.Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging.Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging.Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging.Molecular MR Imaging ProbesMultifunctional imaging nanoprobesMagnetic quantum dots for multimodal imaging.Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications.The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging.Metal-carbonyl units for vibrational and luminescence imaging: towards multimodality.Small BODIPY Probes for Combined Dual (19) F MRI and Fluorescence Imaging.Gadolinium-encapsulating iron oxide nanoprobe as activatable NMR/MRI contrast agent.
P2860
Q24651937-C183C138-C585-4196-B7B9-3A0930D5CC1BQ30407070-28E52D09-6B9D-4074-A103-29EE07F71266Q30433423-9A77234C-6F82-4BE6-9758-C5032B428216Q30472127-C1EF48D2-67E0-4282-BD19-C5E0607672CBQ30479903-7EBD246B-910E-44BE-9817-0ECD5215E723Q30583218-B8555F25-06DC-487C-9F15-64EA28D51D56Q30596925-323A1A7F-9368-4E79-B025-DB7FAD00DF40Q30843582-121EEC2E-7456-4972-ABBC-A6B08474D7CEQ31078041-11AC5D98-E686-497D-91D2-46AA4EDB709DQ31132745-13F7F7F0-8181-4844-987C-7C13DFC17AC4Q33464006-7780449B-88EE-4F12-B2C3-EC9EDC063514Q33470566-4DA0791B-6029-4502-9EAD-06E43ECEA846Q33549945-BD0FF250-2987-43F1-BAA2-A8B928060712Q33623967-2CA5CB85-9084-4202-BB42-621D351B25C9Q33772658-58C8718E-35C2-4BD5-A1AF-E6F19222FDB5Q33847006-EBDAB41A-50DD-4C66-BA67-46308FD7F822Q33884695-A79F2547-0A71-49B6-BE16-D0C5FA407055Q33986132-6FD8BEA4-1022-47F8-BBDA-00ACB2C1788CQ34146460-3CEF6E47-971A-4B6C-A346-E4C0CBDCB220Q34367708-F0AEB747-0346-4609-BD36-910072973D3FQ34406741-7CFF4096-1E0A-4910-8AA4-1BB80F581458Q34462201-3963AC95-D98D-4E33-827B-3E2FF920548AQ34785712-AF521514-ACD6-4B79-98A7-F48B07E79EE1Q35681494-E1DD62C3-61D5-418D-8122-80F766FA5288Q35883228-A66E27D8-6CDC-4A6B-BC31-DBCF736194C9Q36173770-D834E9EB-46B0-4C99-A8A4-49759923EEA3Q36314780-DE934516-83F0-4A40-BBE0-931FE6DE77FCQ36443368-9034452A-EFA3-4C79-B4A7-0F405CEE80F7Q36628900-414D813D-D92C-4150-89E4-EBD582426BAFQ36892360-C28F14D6-FFC6-4250-BADF-59500BA3A1A4Q37010649-9CBA7035-A5BD-4F15-A971-AEDC1EE9887CQ37079267-CFF8D72E-DE64-42C2-8A37-AFFADDA1E8B1Q37663915-BE4F2C60-E367-4717-9CEA-AF3A43F3CA00Q37668366-227DBDCA-5B4D-4EDB-AA96-2A93365BBE81Q37772453-D0509C99-EE4C-41AF-A419-7785D0F5909AQ37919627-0AACE093-7D6F-474C-BECC-7786BDB17BF7Q38080002-DD341504-9547-44AA-9115-CC8DAE90ED21Q38265793-FA715C74-05FD-4A73-A7A5-0728D132E6BAQ38761680-CACF7CA6-F658-4425-BE8B-AD37F736D6FCQ39312451-BDFE1A46-EC41-40AE-9CA7-AC488DF5987A
P2860
Fluorescently detectable magnetic resonance imaging agents.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Fluorescently detectable magnetic resonance imaging agents.
@en
Fluorescently detectable magnetic resonance imaging agents.
@nl
type
label
Fluorescently detectable magnetic resonance imaging agents.
@en
Fluorescently detectable magnetic resonance imaging agents.
@nl
prefLabel
Fluorescently detectable magnetic resonance imaging agents.
@en
Fluorescently detectable magnetic resonance imaging agents.
@nl
P2093
P356
P1476
Fluorescently detectable magnetic resonance imaging agents
@en
P2093
A B Staubli
K Kustedjo
R E Jacobs
P304
P356
10.1021/BC970153K
P50
P577
1998-03-01T00:00:00Z